<code id='320524897C'></code><style id='320524897C'></style>
    • <acronym id='320524897C'></acronym>
      <center id='320524897C'><center id='320524897C'><tfoot id='320524897C'></tfoot></center><abbr id='320524897C'><dir id='320524897C'><tfoot id='320524897C'></tfoot><noframes id='320524897C'>

    • <optgroup id='320524897C'><strike id='320524897C'><sup id='320524897C'></sup></strike><code id='320524897C'></code></optgroup>
        1. <b id='320524897C'><label id='320524897C'><select id='320524897C'><dt id='320524897C'><span id='320524897C'></span></dt></select></label></b><u id='320524897C'></u>
          <i id='320524897C'><strike id='320524897C'><tt id='320524897C'><pre id='320524897C'></pre></tt></strike></i>

          Home / hotspot / Wikipedia

          Wikipedia


          Wikipedia

          author:comprehensive    Page View:27
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In